Toyota|$18.29 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.08 (¥3,723)-1.72%▼ (in JPY terms)
SoftBank|$40.72 (¥6,296)+7.83%▲ (in JPY terms)
MUFG|$23.62 (¥3,652)-1.83%▼ (in JPY terms)
Keyence|$489.69 (¥75,720)-0.32%▼ (in JPY terms)
Nintendo|$52.64 (¥8,139)-1.56%▼ (in JPY terms)
NTT|$1.14 (¥177)-0.73%▼ (in JPY terms)
Takeda|$37.86 (¥5,854)+2.04%▲ (in JPY terms)
Tokyo Electron|$328.01 (¥50,720)-0.41%▼ (in JPY terms)
Recruit|$108.20 (¥16,730)+1.49%▲ (in JPY terms)
ITOCHU|$14.93 (¥2,308)-1.39%▼ (in JPY terms)
Honda|$10.80 (¥1,670)-0.54%▼ (in JPY terms)
Shin-Etsu|$36.91 (¥5,707)-0.75%▼ (in JPY terms)
Tokio Marine|$52.41 (¥8,104)-1.21%▼ (in JPY terms)
Fast Retailing|$431.16 (¥66,670)-0.13%▼ (in JPY terms)
Toyota|$18.29 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.08 (¥3,723)-1.72%▼ (in JPY terms)
SoftBank|$40.72 (¥6,296)+7.83%▲ (in JPY terms)
MUFG|$23.62 (¥3,652)-1.83%▼ (in JPY terms)
Keyence|$489.69 (¥75,720)-0.32%▼ (in JPY terms)
Nintendo|$52.64 (¥8,139)-1.56%▼ (in JPY terms)
NTT|$1.14 (¥177)-0.73%▼ (in JPY terms)
Takeda|$37.86 (¥5,854)+2.04%▲ (in JPY terms)
Tokyo Electron|$328.01 (¥50,720)-0.41%▼ (in JPY terms)
Recruit|$108.20 (¥16,730)+1.49%▲ (in JPY terms)
ITOCHU|$14.93 (¥2,308)-1.39%▼ (in JPY terms)
Honda|$10.80 (¥1,670)-0.54%▼ (in JPY terms)
Shin-Etsu|$36.91 (¥5,707)-0.75%▼ (in JPY terms)
Tokio Marine|$52.41 (¥8,104)-1.21%▼ (in JPY terms)
Fast Retailing|$431.16 (¥66,670)-0.13%▼ (in JPY terms)

2026-07-13 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in the United States as neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer, regardless of whether cisplatin is indicated, in combination with pembrolizumab.”

by

2026-07-13 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in the United States as neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer, regardless of whether cisplatin is indicated, in combination with pembrolizumab.”

Tags: Astellas Pharma Inc.JP3942400007

コメントする

Contact